I D Kostakis1, G C Sotiropoulos2, G Kouraklis2. 1. Second Department of Propedeutic Surgery, "Laiko" General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece. Electronic address: ioannis.kostakis@gmail.com. 2. Second Department of Propedeutic Surgery, "Laiko" General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Abstract
BACKGROUND: Pneumocystis jirovecii is a fungus that causes pneumonia in immunocompromised patients, such as liver transplant recipients. METHODS: We searched the Medline database in September 2013 for articles referring to infections from P. jirovecii in liver transplant recipients, using the terms "liver transplantation" and "pneumocystis." Our search yielded 60 articles, 35 of which were used for our review. RESULTS: P. jirovecii pneumonia (PJP) has an incidence of 1%-11% in liver transplant recipients without prophylaxis and mortality rates of 7%-88%. Most cases occur within the first 7 months after transplantation. When prophylactic treatment with oral trimethoprim-sulfamethoxazole is used, its incidence is only 0%-3%. The duration of its use varies from 3 months to 1 year after the liver transplantation. CONCLUSIONS: PJP has relatively high incidence and high mortality rates in liver transplant recipients without prophylactic treatment, which diminishes or even eliminates its occurrence. Therefore, oral trimethoprim-sulfamethoxazole should be used as prophylaxis for 1 year after the liver transplantation in this population.
BACKGROUND:Pneumocystis jirovecii is a fungus that causes pneumonia in immunocompromised patients, such as liver transplant recipients. METHODS: We searched the Medline database in September 2013 for articles referring to infections from P. jirovecii in liver transplant recipients, using the terms "liver transplantation" and "pneumocystis." Our search yielded 60 articles, 35 of which were used for our review. RESULTS:P. jiroveciipneumonia (PJP) has an incidence of 1%-11% in liver transplant recipients without prophylaxis and mortality rates of 7%-88%. Most cases occur within the first 7 months after transplantation. When prophylactic treatment with oral trimethoprim-sulfamethoxazole is used, its incidence is only 0%-3%. The duration of its use varies from 3 months to 1 year after the liver transplantation. CONCLUSIONS: PJP has relatively high incidence and high mortality rates in liver transplant recipients without prophylactic treatment, which diminishes or even eliminates its occurrence. Therefore, oral trimethoprim-sulfamethoxazole should be used as prophylaxis for 1 year after the liver transplantation in this population.
Authors: Nour Shbaklo; Francesco Tandoi; Tommaso Lupia; Silvia Corcione; Renato Romagnoli; Francesco Giuseppe De Rosa Journal: Biomedicines Date: 2022-06-30
Authors: José Ignacio Fortea; Antonio Cuadrado; Ángela Puente; Paloma Álvarez Fernández; Patricia Huelin; Carmen Álvarez Tato; Inés García Carrera; Marina Cobreros; María Luisa Cagigal Cobo; Jorge Calvo Montes; Carlos Ruiz de Alegría Puig; Juan Carlos Rodríguez SanJuán; Federico José Castillo Suescun; Roberto Fernández Santiago; Juan Andrés Echeverri Cifuentes; Fernando Casafont; Javier Crespo; Emilio Fábrega Journal: J Clin Med Date: 2020-11-06 Impact factor: 4.241